Antibody Information
General Information of This Antibody
Antibody ID | ANI0POCQK |
|||||
---|---|---|---|---|---|---|
Antibody Name | Lonigutamab |
|||||
Organization | Pierre Fabre SA; |
|||||
Indication | Graves ophthalmopathy; Solid tumors |
|||||
Synonyms |
hz208F2-4
Click to Show/Hide
|
|||||
Antibody Type | Monoclonal antibody (mAb) |
|||||
Antibody Subtype | Humanized IgG1-kappa |
|||||
Antigen Name | Insulin-like growth factor 1 receptor (IGF1R) |
Antigen Info | ||||
Click to Show/Hide the Sequence Information of This Antibody | ||||||
Heavy Chain Sequence |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWMGWIWPGDGSTKY
AQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYFCASPMITPNYAMDYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG Click to Show/Hide
|
|||||
Heavy Chain Varible Domain |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWMGWIWPGDGSTKY
AQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYFCASPMITPNYAMDYWGQGTLVTVSS Click to Show/Hide
|
|||||
Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV Click to Show/Hide
|
|||||
Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG Click to Show/Hide
|
|||||
Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
Heavy Chain CDR 1 |
GYTFTSYY
Click to Show/Hide
|
|||||
Heavy Chain CDR 2 |
IWPGDGST
Click to Show/Hide
|
|||||
Heavy Chain CDR 3 |
ASPMITPNYAMDY
Click to Show/Hide
|
|||||
Light Chain Sequence |
DIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPGKAPKLLIYYTSRLQSGVPS
RFSGRGSGTDYSLTISSLQPEDFATYFCQQGSTLPYTFGGGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Light Chain Varible Domain |
DIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPGKAPKLLIYYTSRLQSGVPS
RFSGRGSGTDYSLTISSLQPEDFATYFCQQGSTLPYTFGGGTKVEIK Click to Show/Hide
|
|||||
Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Light Chain CDR 1 |
QDISKY
Click to Show/Hide
|
|||||
Light Chain CDR 2 |
YTS
Click to Show/Hide
|
|||||
Light Chain CDR 3 |
QQGSTLPYT
Click to Show/Hide
|
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Lonigutamab ugodotin [Phase 2]
Identified from the Human Clinical Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Related Clinical Trial | |||||
NCT Number | NCT03316638 | Clinical Status | Phase 1/2 | ||
Clinical Description |
Phase 1/2 open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors. International, multicenter, open label study.
|
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | Low IGF1 expression (IGF1+) | ||
Method Description |
For the lung cancer models, 7-week-old female athymic nude mice (Envigo) were engrafted subcutaneously with 7 x106 SBC5 cells and treated with W0101 or isotype control ADC at 3 mg/kg every 4 days for 4 cycles.
|
||||
In Vitro Model | Lung small cell carcinoma | SBC-5 cells | CVCL_1679 | ||
Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.00% | Moderate IGF1 expression (IGF1++) | ||
Method Description |
For the lung cancer models, 7-week-old female athymic nude mice (Envigo) were engrafted subcutaneously with 7 x106 NCI-H2122 cells and treated with W0101 or isotype control ADC at 3 mg/kg every 4 days for 4 cycles.
|
||||
In Vitro Model | Lung adenocarcinoma | NCI-H2122 cells | CVCL_1531 | ||
Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% | High IGF1 expression (IGF1+++) | ||
Method Description |
For the breast cancer model, 7-week-old female Swiss nude mice (Charles River Laboratories) were engrafted subcutaneously with 5 x106 MCF-7 cells 1 day after subcutaneous implantation of 0.72 mg 17-estradiol 60-day releasing pellets (Innovative Research of America) and treated with W0101 or isotype control ADC at 3 mg/kg every 4 days for 4 cycles.
Click to Show/Hide
|
||||
In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% | Moderate IGF1 expression (IGF1++) | ||
Method Description |
For the ovarian cancer model, 7-week-old female SCID mice (Charles River Laboratories) were engrafted subcutaneously with 10 x106 CaoV3 cells and treated with W0101 or isotype control ADC at 3 mg/kg every 4 days for 4 cycles.
|
||||
In Vitro Model | Lung adenocarcinoma | NCI-H2122 cells | CVCL_1531 | ||
Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.01 nM
|
High IGF1 expression (IGF1+++) | ||
Method Description |
Tumor and normal cells were plated in 96-well flat bottomed microplates (100 L/well) in cell culture medium and incubated overnight at 37°C in 5% CO2. The next day, increasing concentrations of W0101 or isotype control ADC (010 ug/mL) were added into 3 replicate wells containing cells (10 L/well). Plates were incubated for 6 days at 37°C in 5% CO2. Cell viability was determined by measuring ATP using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luminescence was read using a Multimode Microplate Reader (Mithras LB940, Berthold Technologies). The percentage cell viability was calculated for each concentration considering 0 ug/mL ADC as 100% viability. The IC50 was calculated using Prism software. Three independent experiments were performed.
Click to Show/Hide
|
||||
In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.63 nM
|
Moderate IGF1 expression (IGF1++) | ||
Method Description |
Tumor and normal cells were plated in 96-well flat bottomed microplates (100 L/well) in cell culture medium and incubated overnight at 37°C in 5% CO2. The next day, increasing concentrations of W0101 or isotype control ADC (010 ug/mL) were added into 3 replicate wells containing cells (10 L/well). Plates were incubated for 6 days at 37°C in 5% CO2. Cell viability was determined by measuring ATP using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luminescence was read using a Multimode Microplate Reader (Mithras LB940, Berthold Technologies). The percentage cell viability was calculated for each concentration considering 0 ug/mL ADC as 100% viability. The IC50 was calculated using Prism software. Three independent experiments were performed.
Click to Show/Hide
|
||||
In Vitro Model | Lung adenocarcinoma | NCI-H2122 cells | CVCL_1531 | ||
Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 nM | Moderate IGF1 expression (IGF1++) | ||
Method Description |
Tumor and normal cells were plated in 96-well flat bottomed microplates (100 L/well) in cell culture medium and incubated overnight at 37°C in 5% CO2. The next day, increasing concentrations of W0101 or isotype control ADC (010 ug/mL) were added into 3 replicate wells containing cells (10 L/well). Plates were incubated for 6 days at 37°C in 5% CO2. Cell viability was determined by measuring ATP using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luminescence was read using a Multimode Microplate Reader (Mithras LB940, Berthold Technologies). The percentage cell viability was calculated for each concentration considering 0 ug/mL ADC as 100% viability. The IC50 was calculated using Prism software. Three independent experiments were performed.
Click to Show/Hide
|
||||
In Vitro Model | Ovarian serous adenocarcinoma | Caov-3 cells | CVCL_0201 | ||
Experiment 8 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 100.00 nM | Low IGF1 expression (IGF1+) | ||
Method Description |
Tumor and normal cells were plated in 96-well flat bottomed microplates (100 L/well) in cell culture medium and incubated overnight at 37°C in 5% CO2. The next day, increasing concentrations of W0101 or isotype control ADC (010 ug/mL) were added into 3 replicate wells containing cells (10 L/well). Plates were incubated for 6 days at 37°C in 5% CO2. Cell viability was determined by measuring ATP using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luminescence was read using a Multimode Microplate Reader (Mithras LB940, Berthold Technologies). The percentage cell viability was calculated for each concentration considering 0 ug/mL ADC as 100% viability. The IC50 was calculated using Prism software. Three independent experiments were performed.
Click to Show/Hide
|
||||
In Vitro Model | Lung small cell carcinoma | SBC-5 cells | CVCL_1679 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.